Healthcare

Telix Pharmaceuticals has built a fast-growing radiopharmaceutical business around prostate cancer imaging and is using that base to expand into higher-value therapies. Its mix of commercial traction and pipeline ambition makes the company worth a closer analytical look.

Trulieve is a major U.S. cannabis operator with a dominant Florida footprint, broad retail infrastructure, and improving operating discipline. Strong cash generation and a restored operating profit profile make its long-term positioning more interesting than net income alone suggests.

Tecan builds laboratory automation systems and OEM instruments used in research, diagnostics, and biopharma. Its niche positioning, recurring service exposure, and solid balance sheet stand out, while the main debate centers on how strongly earnings recover.

Tarsus Pharmaceuticals is building around XDEMVY, a first approved treatment for Demodex blepharitis. Revenue growth has been exceptionally strong, cash burn has improved, and its niche eye-care position is becoming more meaningful as commercialization scales.

Supernus Pharmaceuticals sells CNS medicines led by Qelbree and Parkinson’s products. Revenue growth has improved, the balance sheet is unusually light on debt, and the company has room to expand through focused portfolio building if it can turn that momentum into steadier profits.

Siegfried Holding AG is a Swiss CDMO serving pharmaceutical companies across drug substances and finished medicines. Strong margins, high returns on capital, and a broad manufacturing network make it a notable healthcare operator worth a closer look.